Basic Information
| LncRNA/CircRNA Name | SNHG16 |
| Synonyms | NA |
| Region | GRCh38_17:76557766-76565348 |
| Ensemble | ENSG00000163597 |
| Refseq | NR_038108 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | Normal human astrocytes (NHAs) and human glioma cell lines U251, LN229 and U87, Normal brain tissues (NBTs) and glioma tissues |
| Expression Pattern | up-regulated |
| Function Description | lncRNA SNHG16 was highly expressed in glioma and may exert oncogenic function as a competing endogenous RNA (ceRNA) to regulate EGFR by sponging of miR-373-3p through activating PI3K/AKT pathway, which providing a new insight of the regulatory network of lncRNA SNHG16 in the development of glioma. |
| Pubmed ID | 31226483 |
| Year | 2019 |
| Title | lncRNA SNHG16 promotes glioma tumorigenicity through miR-373/EGFR axis by activating PI3K/AKT pathway |
External Links
| Links for SNHG16 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |